VAXXEL

Member of Lyonbiopole

Vaxxel is a pre-clinical-stage company developing vaccines against bronchiolitis and viral pneumonia: Metapneumovirus (hMPV) and respiratory Syncytial Virus (hRSV) Vaxxel develops intranasal live-attenuated vaccines (LAVs) based on a proprietary technology based on (i) a genetically modified hMPV developped by the Virology Laboratory of Lyon University and (ii) on a novel avian cell line permissive to hMPV acquired from Transgene

Strategic application domain: Human Medicine

Application market: Infectious Diseases, Pneumology - Respiratory Diseases

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Molecular Biology & Nucleic acid, Vaccine

Created on march 5^th, 2020 - 3 employees

Address

43, Boulevard du 11 Novembre 1918, L’Atrium 69100 Villeurbanne

Visit Website